Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEN003694 in mCRPC
NCT02705469Phase 1Completed
- Sponsor
- Zenith Epigenetics
- Start
- May 2016
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ZEN3694 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Zenith Epigenetics. Primary endpoints: Incidence of dose-limiting toxicities and Incidence of treatment-related adverse events and serious adverse events up to 24 months. Started May 2016; status: completed.
02
Drugs
ZEN3694
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02705469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02705469.